期刊
TRENDS IN PARASITOLOGY
卷 33, 期 3, 页码 162-174出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.pt.2016.11.003
关键词
-
类别
资金
- European Union [642609, FP7-222895]
- Flemish Fund for Scientific Research [12Q8115N, G.O.B81.12]
- Belgian Science Policy Office (TRIT) [P7/41]
- Department of Economy, Science and Innovation in Flanders (ITM-SOFIB)
New drugs are needed to control leishmaniasis and efforts are currently ongoing to counter the neglect of this disease. We discuss here the utility and the impact of associating drug resistance (DR) studies to drug discovery pipelines. We use as paradigm currently used drugs, antimonials and miltefosine, and complement our reflection by interviewing three experts in the field. We suggest DR studies to be involved at two different stages of drug development: (i) the efficiency of novel compounds should be confirmed on sets of strains including recent clinical isolates with DR; (ii) experimental DR should be generated to promising compounds at an early stage of their development, to further optimize them and monitor clinical trials.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据